Clinical and economic challenges facing pharmacogenomics.
about
Emerging roles for pharmacists in clinical implementation of pharmacogenomicsApproval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.Array-based sensing using nanoparticles: an alternative approach for cancer diagnostics.Preemptive clinical pharmacogenetics implementation: current programs in five US medical centersEarly Stage Health Technology Assessment for Precision Biomarkers in Oral Health and Systems Medicine.A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literatureComplexities of CYP2D6 gene analysis and interpretation.Stakeholder views on pharmacogenomic testing.An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.Requirements for comprehensive pharmacogenetic genotyping platforms.Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing.International differences in companion diagnostic approvals: how are we able to manage the differences?Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers.Access to Guideline-Recommended Pharmacogenomic Tests for Cancer Treatments: Experience of Providers and Patients.Automation of diagnostic genetic testing: mutation detection by cyclic minisequencing.Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.
P2860
Q34302434-8C065757-6EA4-4637-8BD5-C14DB585BC6CQ34541294-27AA2B6C-A3FF-44D4-B269-B66F67FD096BQ35621579-98960EA8-4422-4A2B-A68E-04E3CB0788F8Q36166107-A5E95836-BE4E-48FC-9868-29661C8FF8FAQ36538793-B20C1B71-A348-464C-922A-121A598C3205Q36541715-D71715D1-7FB7-4F92-A364-83A23B46EA3DQ36702588-136BA2E1-7137-46C4-915E-8CEC276167D7Q37100793-0BAAE7F0-5E0E-423A-B2B6-3E3BA24AC305Q38154914-DA5E2CA2-04B9-485C-8EE6-22312750F522Q38156135-D2FA62DC-F2A6-4F35-B40A-CF7B3CB52B49Q38257149-E35ACC1C-7343-4ADF-A488-801C877F15AAQ38510741-D8C0A9BF-EFFA-4B7D-8694-C230FAE6D971Q38859829-0884980C-E0DB-4596-A265-1B1B11E62251Q43566770-8E7D2668-484A-41F4-855A-F1E5BF24498BQ46344538-DA01C30E-6014-465D-9C8A-F7F43E08B041Q47277604-3289801C-E687-4D66-AF9F-C24EED29A064Q50001514-D76B1EFA-BDE9-4B10-9517-FB148F331ACAQ50140048-68E10D00-CF46-4F1A-9BDA-4A3531A5C306Q55458851-ACE34A66-74C8-4048-99BF-5D5BBFDC2FDDQ55717925-B92D765D-B82C-4232-8749-25314457267B
P2860
Clinical and economic challenges facing pharmacogenomics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical and economic challenges facing pharmacogenomics.
@en
Clinical and economic challenges facing pharmacogenomics.
@nl
type
label
Clinical and economic challenges facing pharmacogenomics.
@en
Clinical and economic challenges facing pharmacogenomics.
@nl
prefLabel
Clinical and economic challenges facing pharmacogenomics.
@en
Clinical and economic challenges facing pharmacogenomics.
@nl
P2093
P2860
P356
P1476
Clinical and economic challenges facing pharmacogenomics.
@en
P2093
P2860
P2888
P304
P356
10.1038/TPJ.2011.63
P577
2012-01-10T00:00:00Z